Literature DB >> 22447467

Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles.

Wakaya Fujiwara1, Hideo Izawa, Gen Ukai, Hiroatsu Yokoi, Daisuke Mukaide, Kohsuke Kinoshita, Shin-ichiro Morimoto, Junichi Ishii, Yukio Ozaki, Masanori Nomura.   

Abstract

Previous studies have shown highly effective lowering of blood pressure with thiazide diuretics in combination with angiotensin receptor blockers. However, thiazide diuretics may cause the development of diabetes and abnormal lipid metabolism. Little is known as to whether dysmetabolic potential of thiazide diuretics could be neutralized when adding angiotensin receptor blockers. This study consisted of 26 patients with essential hypertension. Patients were randomized to 24 weeks of treatment with either candesartan, 12 mg monotherapy (n = 13, group A), or hydrochlorothiazide (HCTZ), 6.25 mg in combination with candesartan, 8 mg (n = 13, group B). Before and after treatment, we assessed glucose and lipid profiles including adiponectin, resistin, and active glucagon-like peptide-1 (GLP-1) levels. At baseline, there were no differences in age, body mass index, systolic blood pressure (SBP), and diastolic blood pressure (DBP), as well as plasma levels of hemoglobin A1c, insulin, low-density lipoprotein cholesterol, triglycerides, adiponectin, resistin, and active GLP-1 between the two groups. There were significant reductions in SBP (from 152 ± 10 mmHg at baseline to 134 ± 12 mmHg after treatment) and DBP (from 84 ± 5 mmHg at baseline to 71 ± 8 mmHg after treatment) in group A. There were also significant reductions in SBP (from 148 ± 10 at baseline to 128 ± 7 mmHg after treatment) and DBP (from 90 ± 9 at baseline to 74 ± 12 mmHg after treatment) in group B. There were no differences in reduction of SBP or DBP after 24 weeks of treatment between the two groups. There were no changes of the glucose and lipid profiles, including adiponectin, resistin, insulin, and active GLP-1 levels after 24 weeks of treatment in both groups. A low dose of HCTZ in combination with candesartan reduces blood pressure effectively without adverse effects on the glucose and lipid profiles. Therefore, the combination of thiazide diuretics and angiotensin receptor blockers could assist patients in achieving long-term control of blood pressure with good tolerability.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22447467     DOI: 10.1007/s00380-012-0246-5

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  35 in total

1.  Incident diabetes in clinical trials of antihypertensive drugs.

Authors:  Simon Kh Lam; Andrew Owen
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

2.  Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome.

Authors:  Toshihiko Uchida; Minoru Shimizu; Yoshihiko Sakai; Tomoki Nakano; Kenji Hara; Kohzo Takebayashi; Teruo Inoue; Koichi Node; Toshihiko Inukai; Kan Takayanagi; Yoshimasa Aso
Journal:  Metabolism       Date:  2008-09       Impact factor: 8.694

3.  Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.

Authors:  James L Pool; Robert Glazer; Myron Weinberger; Roxanne Alvarado; Jie Huang; Alan Graff
Journal:  Clin Ther       Date:  2007-01       Impact factor: 3.393

4.  Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.

Authors:  Antonio Ceriello; Roberta Assaloni; Roberto Da Ros; Amabile Maier; Ludovica Piconi; Lisa Quagliaro; Katherine Esposito; Dario Giugliano
Journal:  Circulation       Date:  2005-05-02       Impact factor: 29.690

5.  Effects of losartan/hydrochlorothiazide treatment, after change from ARB at usual dosage, on blood pressure and various metabolic parameters including high-molecular weight adiponectin in Japanese male hypertensive subjects.

Authors:  Hiroshi Hirose; Hiroshi Kawabe; Ikuo Saito
Journal:  Clin Exp Hypertens       Date:  2010-12-11       Impact factor: 1.749

6.  Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.

Authors:  Masaki Watanabe; Kouichi Inukai; Takashi Sumita; Kaori Ikebukuro; Daisuke Ito; Susumu Kurihara; Hiraku Ono; Takuya Awata; Shigehiro Katayama
Journal:  Intern Med       Date:  2010-09-01       Impact factor: 1.271

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy.

Authors:  Gerd Bönner
Journal:  Blood Press Suppl       Date:  2008-12

10.  Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.

Authors:  Kirsten Vollmer; Jens J Holst; Birgit Baller; Mark Ellrichmann; Michael A Nauck; Wolfgang E Schmidt; Juris J Meier
Journal:  Diabetes       Date:  2007-12-05       Impact factor: 9.461

View more
  4 in total

Review 1.  The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.

Authors:  Hazel Mae A Abraham; C Michael White; William B White
Journal:  Drug Saf       Date:  2015-01       Impact factor: 5.606

2.  Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial.

Authors:  Toru Miyoshi; Atsushi Hirohata; Shinichi Usui; Keizo Yamamoto; Takashi Murakami; Issei Komatsubara; Shozo Kusachi; Tohru Ohe; Kazufumi Nakamura; Hiroshi Ito
Journal:  Heart Vessels       Date:  2013-04-07       Impact factor: 2.037

Review 3.  Association of Thiazide-Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.

Authors:  Xiaodan Zhang; Qingyu Zhao
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-09-23       Impact factor: 3.738

4.  Impact of chronic diuretic treatment on glucose homeostasis.

Authors:  Silvio Buscemi; Antonio Nicolucci; Giuseppe Lucisano; Fabio Galvano; Giuseppe Grosso; Fatima M Massenti; Emanuele Amodio; Alice Bonura; Delia Sprini; Giovam B Rini
Journal:  Diabetol Metab Syndr       Date:  2013-12-13       Impact factor: 3.320

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.